Xeris Biopharma Holdings Profit Margin

The latest profit margin for XERS is -5.12% as of June 2026. That compares with -13.08% in the prior-year period — up 60.9% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Xeris Biopharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, XERS's profit margin moved from -13.08% to -5.12% — a 60.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xeris Biopharma Holdings's valuation or profitability profile.

Against Healthcare companies, XERS currently prints -5.12% for profit margin, while the sector average sits near 14.34%. That is roughly 135.7% below the sector mean. Large gaps often invite a closer look at Xeris Biopharma Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively Xeris Biopharma Holdings converts resources into returns. At -5.12%, XERS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13.08% in the prior-year period — up 60.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XERS's profit margin (-5.12%), review year-over-year change from -13.08%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.